Apolipoprotein E E3/E4 genotype is associated with an increased risk of coronary atherosclerosis in patients with hypertension.
Humans
Male
Female
Coronary Artery Disease
/ genetics
Middle Aged
Hypertension
/ genetics
Retrospective Studies
Genetic Predisposition to Disease
Risk Assessment
Aged
Risk Factors
Apolipoprotein E3
/ genetics
Apolipoprotein E4
/ genetics
China
/ epidemiology
Phenotype
Polymorphism, Single Nucleotide
Genetic Association Studies
Apolipoproteins E
APOE
Coronary atherosclerosis
Hypertension
Susceptibility
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
21
05
2024
accepted:
05
09
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
Apolipoprotein E (APOE) gene polymorphisms were associated with coronary atherosclerosis and hypertension. However, the relationship between APOE polymorphisms and coronary atherosclerosis susceptibility in hypertensive patients is unclear. The aim of this study was to assess the relationship. A total of 1713 patients with hypertension who were admitted to Meizhou People's Hospital from November 2019 to August 2023 were retrospectively analyzed, including 848 patients with coronary atherosclerosis and 865 patients without coronary atherosclerosis. The rs429358 and rs7412 polymorphisms of APOE were genotyped, and relationship between APOE polymorphisms and the risk of coronary atherosclerosis in hypertensive patients were analyzed. There were 10 (0.6%), 193 (11.3%), 30 (1.8%), 1234 (72.0%), 233 (13.6%), and 13 (0.8%) individuals with APOE ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ɛ3, ɛ3/ɛ4, and ɛ4/ɛ4 genotype, respectively. The frequency of APOE ɛ3/ɛ4 was higher (16.4% vs. 10.9%, p = 0.001) in the patients with coronary atherosclerosis than controls. Logistic analysis showed that body mass index (BMI) ≥ 24.0 kg/m Overweight (BMI ≥ 24.0 kg/m
Identifiants
pubmed: 39261765
doi: 10.1186/s12872-024-04169-3
pii: 10.1186/s12872-024-04169-3
doi:
Substances chimiques
ApoE protein, human
0
Apolipoprotein E3
0
Apolipoprotein E4
0
Apolipoproteins E
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
486Informations de copyright
© 2024. The Author(s).
Références
Aune D, Mahamat-Saleh Y, Kobeissi E, Feng T, Heath AK, Janszky I. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38(2):145–78.
pubmed: 36626102
pmcid: 9905193
doi: 10.1007/s10654-022-00914-0
Worldwide trends in. Hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.
doi: 10.1016/S0140-6736(21)01330-1
Zhang M, Shi Y, Zhou B, Huang Z, Zhao Z, Li C, Zhang X, Han G, Peng K, Li X, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey. BMJ. 2023;380:e071952.
pubmed: 36631148
pmcid: 10498511
doi: 10.1136/bmj-2022-071952
Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15(3):134–6.
pubmed: 23536128
pmcid: 3699411
doi: 10.1007/s11906-013-0340-9
Pickering GW. The natural history of hypertension. Br Med Bull. 1952;8(4):305–9.
pubmed: 12987687
doi: 10.1093/oxfordjournals.bmb.a074193
Yin R, Yin L, Li L, Silva-Nash J, Tan J, Pan Z, Zeng J, Yan LL. Hypertension in China: burdens, guidelines and policy responses: a state-of-the-art review. J Hum Hypertens. 2022;36(2):126–34.
pubmed: 34215840
doi: 10.1038/s41371-021-00570-z
Gaidai O, Cao Y, Loginov S. Global Cardiovascular diseases Death Rate Prediction. Curr Probl Cardiol. 2023;48(5):101622.
pubmed: 36724816
doi: 10.1016/j.cpcardiol.2023.101622
Shaya GE, Leucker TM, Jones SR, Martin SS, Toth PP. Coronary heart disease risk: low-density lipoprotein and beyond. Trends Cardiovasc Med. 2022;32(4):181–94.
pubmed: 33872757
doi: 10.1016/j.tcm.2021.04.002
Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary atherosclerosis and clinical implications for chronic ischemic heart Disease Management-the Plaque hypothesis: a narrative review. JAMA Cardiol. 2023;8(2):192–201.
pubmed: 36515941
pmcid: 11016334
doi: 10.1001/jamacardio.2022.3926
Andersson C, Johnson AD, Benjamin EJ. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;16(11):687–98.
pubmed: 31065045
doi: 10.1038/s41569-019-0202-5
Park H, Kim D, European, Guideline-Based US. Statin eligibility, genetically predicted coronary artery Disease, and the risk of major coronary events. J Am Heart Assoc. 2024;13(9):e032831.
pubmed: 38639378
pmcid: 11179899
doi: 10.1161/JAHA.123.032831
Wang L, Li X, Li T, Liu L, Wang H, Wang C. Novel application of drug-coated balloons in coronary heart disease: a narrative review. Front Cardiovasc Med. 2023;10:1055274.
pubmed: 36937937
pmcid: 10017483
doi: 10.3389/fcvm.2023.1055274
Flora GD, Nayak MK. A brief review of Cardiovascular diseases, Associated Risk factors and current treatment regimes. Curr Pharm Des. 2019;25(38):4063–84.
pubmed: 31553287
doi: 10.2174/1381612825666190925163827
Sarebanhassanabadi M, Mirjalili SR. Coronary artery disease incidence, risk factors, awareness, and medication utilization in a 10-year cohort study. BMC Cardiovasc Disord. 2024;24(1):101.
pubmed: 38347457
pmcid: 10863377
doi: 10.1186/s12872-024-03769-3
Aronow WS. Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. Expert Opin Pharmacother. 2016;17(2):205–15.
pubmed: 26373919
doi: 10.1517/14656566.2015.1091881
Dong L, Liu J, Qin Y, Yang WJ, Nie L, Liu HN, Hu QH, Sun Y, Cao WY. Relationship between ambulatory arterial stiffness index and the severity of angiographic atherosclerosis in patients with H-type hypertension and coronary artery disease. Clin Exp Hypertens. 2023;45(1):2228517.
pubmed: 37358029
doi: 10.1080/10641963.2023.2228517
Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899–911.
pubmed: 24881994
pmcid: 4042017
doi: 10.1016/S0140-6736(14)60685-1
Yim J, Rabkin SW. A patient-specific approach to assessing blood pressure management in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich). 2018;20(2):233–9.
pubmed: 29370480
doi: 10.1111/jch.13191
Huang XD, Lin JY, Huang XW, Zhou TT, Xie LD. A nomogram based on endothelial function and conventional risk factors predicts coronary artery disease in hypertensives. BMC Cardiovasc Disord. 2023;23(1):217.
pubmed: 37118701
pmcid: 10148409
doi: 10.1186/s12872-023-03235-6
Alenazi AM, Alqahtani BA. National and regional prevalence rates of hypertension in Saudi Arabia: a descriptive analysis using the national survey data. Front Public Health. 2023;11:1092905.
pubmed: 37081959
pmcid: 10110943
doi: 10.3389/fpubh.2023.1092905
Wang J, Ma JJ, Liu J, Zeng DD, Song C, Cao Z. Prevalence and risk factors of comorbidities among hypertensive patients in China. Int J Med Sci. 2017;14(3):201–12.
pubmed: 28367080
pmcid: 5370282
doi: 10.7150/ijms.16974
Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006;33(3):279–308.
pubmed: 17092867
doi: 10.1080/03014460600594513
Tersigni C, Furqan Bari M, Cai S, Zhang W, Kandzija N, Buchan A, Miranda F, Di Simone N, Redman CW, Bastie C, et al. Syncytiotrophoblast-derived extracellular vesicles carry apolipoprotein-E and affect lipid synthesis of liver cells in vitro. J Cell Mol Med. 2022;26(1):123–32.
pubmed: 34894055
doi: 10.1111/jcmm.17056
Hong S, Washington PM, Kim A, Yang CP, Yu TS, Kernie SG. Apolipoprotein E regulates Injury-Induced activation of hippocampal neural stem and progenitor cells. J Neurotrauma. 2016;33(4):362–74.
pubmed: 25905575
pmcid: 4761847
doi: 10.1089/neu.2014.3860
Zhu K, Zhang H. KDM4C promotes mouse hippocampal neural stem cell proliferation through modulating ApoE expression. FASEB J. 2024;38(5):e23511.
pubmed: 38421303
doi: 10.1096/fj.202302439R
Rahmany S, Jialal I. Biochemistry, Chylomicron. StatPearls. Edn. Treasure Island (FL) ineligible companies. Disclosure: Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC.; 2024.
Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51(2):165–76.
pubmed: 30598326
doi: 10.1016/j.pathol.2018.11.002
Khalil YA, Rabès JP, Boileau C, Varret M. APOE gene variants in primary dyslipidemia. Atherosclerosis. 2021;328:11–22.
pubmed: 34058468
doi: 10.1016/j.atherosclerosis.2021.05.007
Lan X, Wang Z, Zeng Z, Yao H, Xu W, Zhang Y. Association of different combinations of ALDH2 rs671, APOE rs429358, rs7412 polymorphisms with hypertension in Middle-aged and Elderly people: a case-control study. Int J Gen Med. 2023;16:915–27.
pubmed: 36938306
pmcid: 10017832
doi: 10.2147/IJGM.S402437
Seripa D, D’Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011;14(5):491–500.
pubmed: 21958003
doi: 10.1089/rej.2011.1169
Chen W, Li B, Wang H, Wei G, Chen K, Wang W, Wang S, Liu Y. Apolipoprotein E E3/E4 genotype is associated with an increased risk of type 2 diabetes mellitus complicated with coronary artery disease. BMC Cardiovasc Disord. 2024;24(1):160.
pubmed: 38491412
pmcid: 10941446
doi: 10.1186/s12872-024-03831-0
Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66(9):616–23.
pubmed: 25328986
doi: 10.1002/iub.1314
Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012–2015. Circulation. 2018;137(22):2344–56.
pubmed: 29449338
doi: 10.1161/CIRCULATIONAHA.117.032380
Lee SE, Sung JM, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, et al. Quantification of coronary atherosclerosis in the Assessment of Coronary Artery Disease. Circ Cardiovasc Imaging. 2018;11(7):e007562.
pubmed: 30012825
doi: 10.1161/CIRCIMAGING.117.007562
Liu J, Huang S, Wang X, Li B, Ma J, Sun H, Xi X, Sun Y, Zhang L, Liu J, et al. Effect of the coronary arterial diameter derived from coronary computed tomography angiography on fractional Flow Reserve. J Comput Assist Tomogr. 2022;46(3):397–405.
pubmed: 35483102
doi: 10.1097/RCT.0000000000001299
He W, Li Q, Yang M, Jiao J, Ma X, Zhou Y, Song A, Heymsfield SB, Zhang S, Zhu S. Lower BMI cutoffs to define overweight and obesity in China. Obesity. 2015;23(3):684–91.
pubmed: 25645003
doi: 10.1002/oby.20995
Tang J, Zhu X, Chen Y, Huang D, Tiemeier H, Chen R, Bao W, Zhao Q. Association of maternal pre-pregnancy low or increased body mass index with adverse pregnancy outcomes. Sci Rep. 2021;11(1):3831.
pubmed: 33589654
pmcid: 7884680
doi: 10.1038/s41598-021-82064-z
Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin J Cardiovasc Dis. 2007;35(5):390–419.
Pan L, Yang Z, Wu Y, Yin RX, Liao Y, Wang J, Gao B, Zhang L. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2–9.
pubmed: 26978581
doi: 10.1016/j.atherosclerosis.2016.02.006
Brathwaite L, Reif M. Hypertensive emergencies: a review of Common presentations and Treatment options. Cardiol Clin. 2019;37(3):275–86.
pubmed: 31279421
doi: 10.1016/j.ccl.2019.04.003
Piskorz D. Hypertensive mediated organ damage and Hypertension Management. How to assess Beneficial effects of Antihypertensive treatments? High Blood Press Cardiovasc Prev. 2020;27(1):9–17.
pubmed: 31975151
doi: 10.1007/s40292-020-00361-6
Yoon YH, Park GM. Association of Stage 1 hypertension defined by the ACC/AHA 2017 Guideline with Asymptomatic Coronary atherosclerosis. Am J Hypertens. 2021;34(8):858–66.
pubmed: 33735371
doi: 10.1093/ajh/hpab051
Park HW, Jo S, Park KS, Lee H, Jeon YJ, Park S, Ann SH, Kim YG, Choi SH, Kwon WJ, et al. Differential Impact of Degree of Hypertension on subclinical coronary atherosclerosis in asymptomatic subjects with and without diabetes Mellitus. Am J Cardiol. 2023;203:343–51.
pubmed: 37517130
doi: 10.1016/j.amjcard.2023.07.036
Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med. 2021;8:798958.
doi: 10.3389/fmed.2021.798958
Liu J, Hong Y, D’Agostino RB, Sr., Wu Z, Wang W, Sun J, Wilson PW, Kannel WB, Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-provincial Cohort Study. JAMA. 2004;291(21):2591–9.
pubmed: 15173150
doi: 10.1001/jama.291.21.2591
Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 2012;125(1):37–44.
pubmed: 22184621
doi: 10.1161/CIRCULATIONAHA.110.002774
Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335(7617):432.
pubmed: 17704543
pmcid: 1962877
doi: 10.1136/bmj.39269.672188.AE
Cavallari I, Cannon CP, Braunwald E, Goodrich EL, Im K, Lukas MA, O’Donoghue ML. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018;25(8):830–8.
pubmed: 29537291
doi: 10.1177/2047487318763897
Karjalainen JP, Mononen N, Hutri-Kähönen N, Lehtimäki M, Hilvo M, Kauhanen D, Juonala M, Viikari J, Kähönen M, Raitakari O, et al. New evidence from plasma ceramides links apoE polymorphism to greater risk of coronary artery disease in Finnish adults. J Lipid Res. 2019;60(9):1622–9.
pubmed: 31270131
pmcid: 6718445
doi: 10.1194/jlr.M092809
Abd El-Aziz TA, Mohamed RH. LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease. Gene. 2016;590(2):263–9.
pubmed: 27236033
doi: 10.1016/j.gene.2016.05.032
Afroze D, Yousuf A, Tramboo NA, Shah ZA, Ahmad A. ApoE gene polymorphism and its relationship with coronary artery disease in ethnic Kashmiri population. Clin Exp Med. 2016;16(4):551–6.
pubmed: 26409839
doi: 10.1007/s10238-015-0389-7
Ma W, Ren X, Zhang L, Dong H, Lu X, Feng W. Apolipoprotein E gene polymorphism and coronary artery Disease Risk among patients in Northwest China. Pharmgenomics Pers Med. 2021;14:1591–9.
pubmed: 34908864
pmcid: 8665779
Liu Q, Wu H. APOE gene ɛ4 allele (388 C-526 C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population. J Clin Lab Anal. 2021;35(9):e23925.
pubmed: 34313350
pmcid: 8418481
doi: 10.1002/jcla.23925
Balcerzyk A, Zak I, Krauze J. Synergistic effects of apolipoprotein E gene epsilon polymorphism and some conventional risk factors on premature ischaemic heart disease development. Kardiol Pol. 2007;65(9):1058–65. discussion 1066 – 1057.
pubmed: 17975753
Luo JQ, Ren H, Banh HL, Liu MZ, Xu P, Fang PF, Xiang DX. The associations between Apolipoprotein E Gene Epsilon2/Epsilon3/Epsilon4 polymorphisms and the risk of coronary artery disease in patients with type 2 diabetes Mellitus. Front Physiol. 2017;8:1031.
pubmed: 29311965
pmcid: 5732920
doi: 10.3389/fphys.2017.01031
Karahan Z, Uğurlu M, Uçaman B, Uluğ AV, Kaya İ, Çevik K, Öztürk Ö, Iyem H. Relation between Apolipoprotein E Gene Polymorphism and Severity of Coronary Artery Disease in Acute Myocardial Infarction. Cardiol Res Pract. 2015; 2015:363458.
Long Y, Zhao XT, Liu C, Sun YY, Ma YT, Liu XY, Liu JX. A Case-Control Study of the Association of the Polymorphisms of MTHFR and APOE with risk factors and the severity of coronary artery disease. Cardiology. 2019;142(3):149–57.
pubmed: 31163415
doi: 10.1159/000499866
Petrovic D, Zorc M, Peterlin B. Effect of apolipoprotein E polymorphism and apolipoprotein A-1 gene promoter polymorphism on lipid parameters and premature coronary artery disease. Folia Biol. 2000;46(5):181–5.
Pitsavos C, Choumerianou DM, Skoumas J, Maumus S, Stefanadis C, Dedoussis GV, Visvikis-Siest S. Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin Exp Med. 2005;5(4):196–201.
pubmed: 16362800
doi: 10.1007/s10238-005-0086-z
Formentini FS, Zaina Nagano FE, Lopes Neto FDN, Adam EL, Fortes FS, Silva LFD. Coronary artery disease and body mass index: what is the relationship? Clin Nutr ESPEN. 2019;34:87–93.
Wang K, Shi X, Zhu Z, Hao X, Chen L, Cheng S, Foo RSY, Wang C. Mendelian randomization analysis of 37 clinical factors and coronary artery disease in east Asian and European populations. Genome Med. 2022;14(1):63.
pubmed: 35698167
pmcid: 9195360
doi: 10.1186/s13073-022-01067-1
Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;143(21):e984–1010.
pubmed: 33882682
pmcid: 8493650
doi: 10.1161/CIR.0000000000000973
Choi J, Wen W, Jia G, Tao R, Long J, Shu XO, Zheng W. Lifestyle factors, genetic susceptibility to obesity and their interactions on coronary artery disease risk: a cohort study in the UK Biobank. Prev Med. 2024;180:107886.
pubmed: 38316272
doi: 10.1016/j.ypmed.2024.107886
Lowenstern A, Ng N, Takagi H. Influence of obesity on coronary artery disease and clinical outcomes in the ADVANCE Registry. Circ Cardiovasc Imaging. 2023;16(5):e014850.
pubmed: 37192296
doi: 10.1161/CIRCIMAGING.122.014850
Šteiner I, Krbal L. Is obesity a risk factor for coronary atherosclerosis? Cesk Patol. 2022;58(2):112–4.
pubmed: 35882546
Qu Y, Yang J, Zhang F, Li C, Dai Y, Yang H, Gao Y, Pan Y, Yao K, Huang D, et al. Relationship between body mass index and outcomes of coronary artery disease in Asian population: insight from the FOCUS registry. Int J Cardiol. 2020;300:262–7.
pubmed: 31685245
doi: 10.1016/j.ijcard.2019.10.025
Feng X, Zhang C, Jiang L, Xu L, Tian J, Zhao X, Wang D, Zhang Y, Sun K, Xu B, et al. Body mass index and mortality in patients with severe coronary artery diseases: a cohort study from China. Nutr Metab Cardiovasc Dis. 2021;31(2):448–54.
pubmed: 33223401
doi: 10.1016/j.numecd.2020.09.011
Ashwell M, Gibson S. Waist-to-height ratio as an indicator of ‘early health risk’: simpler and more predictive than using a ‘matrix’ based on BMI and waist circumference. BMJ Open. 2016;6(3):e010159.
pubmed: 26975935
pmcid: 4800150
doi: 10.1136/bmjopen-2015-010159
Kondo T, Nakano Y, Adachi S, Murohara T. Effects of Tobacco Smoking on Cardiovascular Disease. Circ J. 2019;83(10):1980–5.
pubmed: 31462607
doi: 10.1253/circj.CJ-19-0323
Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647–58.
pubmed: 16920470
doi: 10.1016/S0140-6736(06)69249-0
Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol. 2013;33(7):1460–7.
pubmed: 23685556
doi: 10.1161/ATVBAHA.112.300154